# EpimAb Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epimab-biotherapeutics

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.epimab.com
- Total disclosed funding: $220M
- Latest round: Series C (Jun 1, 2021)
- Investors on record: 15

## About

Based in Shanghai, China, founded in 2015, EpimAb Biotherapeutics, Inc., operates as a biopharmaceutical company that develops bi-specific antibodies therapeutics. The company was founded by Chengbin Wu is the founder of EpimAb Biotherapeutics and he was the Senior VP Biologics at Shanghai ChemPartner. Before that he was a Volwiler Associate Fellow at Abbott laboratories, USA. In 2017, EpimAb is supported by an international consortium of investors and has raised $25 million in a Series A financing round to advance the Company’s pipeline of novel bispecific antibodies. In March 2021, EpimAb Biotherapeutics, Inc. raised its latest Series C funding from CMB International Capital Management and Mirae Asset Financial Group.

EpimAb Biotherapeutics, Inc. engages in providing research and development via FIT-Ig (Fabs-In-Tandem) technology, which is based on the scientific rationale to combine the functions of two parental antibodies into one single molecule. This is achieved by re-arranging the DNA sequences of two monoclonal antibodies into three constructs and co-expressing them in mammalian cells. The products pipelines of the company include EMB-01, EMB-06, EMB-09,and can be used in oncology immunity field.

EpimAb Biotherapeutics, Inc. plans to use its funding from March to fund the ongoing clinical development of EMB-01, EMB-02, EMB-06, and to expand the company’s pipeline of novel bispecific antibodies and other biologics.

## Funding rounds

- Series C, Jun 1, 2021, $1M — Calor Capital
- Series C, Mar 22, 2021, $120M — Hony Capital, Decheng Capital, CMB International Asset Management, CS Capital, Yanyuan Capital, Mirae Asset Financial Group, Hidragon Capital, Calor Capital, Sherpa Healthcare Partners, Octagon Capital Advisors, Yuying Asset Management
- Series B, Jun 5, 2019, $74M — CS Capital, South China Venture Capital, Sherpa Healthcare Partners
- Series A, Apr 25, 2017, $25M — Oriza Holdings, Decheng Capital, 3E Bioventures Capital, Trend Investment Group

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A, Series C
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A
- Trend Investment Group (https://capitalatlas.ai/funds/trend-investment-group) — Series A
- CS Capital — Series B, Series C
- South China Venture Capital (https://capitalatlas.ai/funds/south-china-venture-capital) — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B, Series C
- Hony Capital (https://capitalatlas.ai/funds/hony-capital) — Series C
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series C
- Yanyuan Capital — Series C
- Mirae Asset Financial Group — Series C
- Hidragon Capital (https://capitalatlas.ai/funds/hidragon-capital) — Series C
- Calor Capital (https://capitalatlas.ai/funds/calor-capital) — Series C
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series C
- Yuying Asset Management — Series C